Sanofi declined to comment to Pharmaceutical ... preventative antibody Beyfortus (nirsevimab), developed in partnership with AstraZeneca. Positive financial guidance comes despite uncertainty ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

L’Oreal OR0.54%increase; green up pointing triangle will sell part of its stake in Sanofi SAN 0.43%increase; green up pointing triangle back to the French pharmaceutical company for 3 billion ...

vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca. Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

“Nirsevimab protected against RSV single and coinfections, with no evidence of replacement of RSV with other respiratory viruses,” the researchers concluded. Disclosure: This research was supported by ...

vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca. Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme in ...

The one-off therapy, nirsevimab, is designed to protect again illness from respiratory syncytial virus (RSV) which can be deadly for infants. RSV is one of a number of viruses that surge in winter ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...

The Sanofi Global Health Unit plays an important ... we have a competitive profile with nirsevimab. We have an extensive amount of real-world evidence. You've seen many countries showing 80% ...

states and territories are picking up the tab for Sanofi-Aventis’ nirsevimab (sold as Beyfortus) for infants. This is widely used, and funded, in the US and Europe. The cost of the vaccine is $300.